IBRX
Price
$5.49
Change
+$0.55 (+11.13%)
Updated
Apr 23, 6:59 PM EST
13 days until earnings call
LCTX
Price
$1.14
Change
-$0.01 (-0.88%)
Updated
Apr 23, 6:59 PM EST
15 days until earnings call
Ad is loading...

IBRX vs LCTX ᐉ Comparison: Which is Better to Invest?

Header iconIBRX vs LCTX Comparison
Open Charts IBRX vs LCTXBanner chart's image
ImmunityBio
Price$5.49
Change+$0.55 (+11.13%)
Volume$16.92M
CapitalizationN/A
Lineage Cell Therapeutics
Price$1.14
Change-$0.01 (-0.88%)
Volume$143.16K
CapitalizationN/A
View a ticker or compare two or three
IBRX vs LCTX Comparison Chart

Loading...

IBRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
LCTXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
IBRX vs. LCTX commentary
Apr 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a Hold and LCTX is a Hold.

COMPARISON
Comparison
Apr 24, 2024
Stock price -- (IBRX: $4.94 vs. LCTX: $1.14)
Brand notoriety: IBRX and LCTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 120% vs. LCTX: 44%
Market capitalization -- IBRX: $3.72B vs. LCTX: $214.93M
IBRX [@Biotechnology] is valued at $3.72B. LCTX’s [@Biotechnology] market capitalization is $214.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $557.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.53B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 0 FA rating(s) are green whileLCTX’s FA Score has 0 green FA rating(s).

  • IBRX’s FA Score: 0 green, 5 red.
  • LCTX’s FA Score: 0 green, 5 red.
According to our system of comparison, IBRX is a better buy in the long-term than LCTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 2 TA indicator(s) are bullish while LCTX’s TA Score has 5 bullish TA indicator(s).

  • IBRX’s TA Score: 2 bullish, 6 bearish.
  • LCTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LCTX is a better buy in the short-term than IBRX.

Price Growth

IBRX (@Biotechnology) experienced а -5.73% price change this week, while LCTX (@Biotechnology) price change was -8.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.03%. For the same industry, the average monthly price growth was +4.97%, and the average quarterly price growth was +1257.50%.

Reported Earning Dates

IBRX is expected to report earnings on Aug 05, 2024.

LCTX is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (+10.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for IBRX with price predictions.
OPEN
A.I.dvisor published
a Summary for LCTX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
IBRX($3.72B) has a higher market cap than LCTX($215M). LCTX YTD gains are higher at: 4.587 vs. IBRX (-1.594).
IBRXLCTXIBRX / LCTX
Capitalization3.72B215M1,729%
EBITDAN/AN/A-
Gain YTD-1.5944.587-35%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
IBRX vs LCTX: Fundamental Ratings
IBRX
LCTX
OUTLOOK RATING
1..100
5974
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3559
P/E GROWTH RATING
1..100
10063
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LCTX's Valuation (51) in the null industry is somewhat better than the same rating for IBRX (94) in the Biotechnology industry. This means that LCTX’s stock grew somewhat faster than IBRX’s over the last 12 months.

IBRX's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as LCTX (100) in the null industry. This means that IBRX’s stock grew similarly to LCTX’s over the last 12 months.

LCTX's SMR Rating (96) in the null industry is in the same range as IBRX (100) in the Biotechnology industry. This means that LCTX’s stock grew similarly to IBRX’s over the last 12 months.

IBRX's Price Growth Rating (35) in the Biotechnology industry is in the same range as LCTX (59) in the null industry. This means that IBRX’s stock grew similarly to LCTX’s over the last 12 months.

LCTX's P/E Growth Rating (63) in the null industry is somewhat better than the same rating for IBRX (100) in the Biotechnology industry. This means that LCTX’s stock grew somewhat faster than IBRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXLCTX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 27 days ago
79%
Declines
ODDS (%)
Bearish Trend 14 days ago
88%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
IBRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
LCTXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGOAX46.540.54
+1.17%
Hartford Growth Opportunities A
FOPTX18.880.17
+0.91%
Fidelity Advisor Intl Sm Cap Opps M
ABVCX17.680.11
+0.63%
AB Value C
HLFMX7.540.03
+0.40%
Harding Loevner Frontier Emerg Mkts Inst
GLOIX12.070.04
+0.33%
Gabelli International Small Cap I

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with MDGL. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-6.26%
MDGL - IBRX
61%
Loosely correlated
+0.68%
AXON - IBRX
48%
Loosely correlated
+0.07%
ARRY - IBRX
41%
Loosely correlated
+3.73%
CRSP - IBRX
40%
Loosely correlated
+1.11%
AMRN - IBRX
37%
Loosely correlated
+0.74%
More

LCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
-0.87%
MDGL - LCTX
43%
Loosely correlated
+0.68%
CMPX - LCTX
35%
Loosely correlated
+1.36%
BCAB - LCTX
34%
Loosely correlated
+3.56%
AXON - LCTX
33%
Loosely correlated
+0.07%
KPTI - LCTX
31%
Poorly correlated
-3.42%
More